Overview
This is the only QPPV Forum designed for QPPVs by QPPVs, now in its 12th year and still going strong. This Forum continues to identify key trends requiring QPPV awareness, input and oversight. This year’s objectives, as shown below, build on past successes and have been shaped by valuable feedback provided by participants of the past eleven meetings, plus many years of QPPV and Regulator interaction at this Forum.
Over time, one of the key successes of the Forum has been the ability to secure continuing support and involvement of key regulators. Sessions have been open and interactive with attendees appreciating opportunities to raise challenging issues in an informal environment. This 12th QPPV Forum continues this successful approach.
Featured
Short Course or Primer
-
Oct 09, 2018
Introduction to the Role of QPPVs
Learn more -
Oct 09, 2018
The PSMF: Where Are We Today and Where Do We Want to Go?
Learn more
What you will learn
Program Committee
-
Elspeth McIntosh, MBA, RN • Director
Castle Pharmacovigilance Ltd, United Kingdom -
Margaret Anne Walters • Deputy EU Qualified Person for Pharmacovigilance
Merck, Sharp & Dohme Ltd, United Kingdom -
Vicki Edwards, RPh • Vice President, Pharmacovigilance Excellence and International QPPV
AbbVie, United Kingdom -
Doris Irene Stenver, MD, MPA • Independent Pharmacovigilance Adviser
Unique Advice, Denmark -
Brian Edwards, DrMed • Vice President
International Society of Pharmacovigilance, United Kingdom -
Michael Richardson, MD, FFPM, FRCP • Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom -
Winrich Rauschning, DrMed, MD, MBA • QPPV
Biolitec Pharma, Germany -
Barbara De Bernardi, MD • EUQPPV Vice President - Head of Global QPPV Office
Pfizer S.r.l., Italy -
Peter De Veene, MD • EU QPPV
Incyte, Belgium -
Angela Van Der Salm, PhD, MSc • Director PV, Managing partner
DADA Consultancy B.V., Netherlands -
Magnus Ysander, MD • EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden